Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

Exclusion Criteria

• •Subject has developed hypersensitivity to any components of the Investigational Medicinal Product (IMP) or comparative drugs as stated in the protocol during the course of the prior study
• •Severe medical, neurological, or psychiatric disorders, or laboratory values that may have an impact on the safety of the subject
• •Poor compliance with the visit schedule or medication intake in the previous BRV study
• •Planned participation in any other clinical study of another investigational drug or device during this study
• •Pregnant or lactating woman
• •Any medical condition which, in the investigator's opinion, warrants exclusion
• •Subject has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to either question 4 or question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at the last visit of the previous study or at the Entry Visit of this study if not completed at the last visit of the previous study